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LETTERS TO THE EDITOR
Antiretroviral drugs and the
kidney: Further precisions
To the Editor: We read with interest the excellent arti-
cle of Daugas et al [1] on HAART-related nephropathies
and we would like to clarify several points.
There has been no case report of Fanconi syndrome
(FS) related to reverse transcriptase inhibitors (RTIs)
except one induced by didanosine [2]. Actually, the sus-
pected case of nevirapine-induced FS was largely related
to lactic acidosis rather than renal tubular acidosis, con-
sidering the anion gap that was increased [3].
It is speculative to incriminate enfuvirtide as a poten-
tial cause of membranoproliferative glomerulonephritis
(MPGN). Indeed, the diagnosis of MPGN was made on
a renal biopsy performed after 57 days of enfuvirtide
therapy together with tenofovir, lamivudine, lopinavir-
ritonavir, amprenavir, and efavirenz, and in a patient
with a history of diabetes and seasonal allergies. Further-
more, in this patient, renal abnormalities (proteinuria and
hematuria) were already present before enfuvirtide was
started [4].
Finally, the entire chapter on nucleotide reverse tran-
scriptase inhibitors (NtRTIs) is confusing with regard to
adefovir potential renal toxicity. Effectively, it is crucial
to specify that at its normal dosage of 10 mg daily for the
treatment of (hepatitis B virus) HBV infection, adefovir
is not nephrotoxic [5]. Furthermore, cidofovir at 3 mg/kg
for BK virus infection has also been reported not to be
nephrotoxic [6].
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Hypotonic fluids should not be
used in volume-depleted
children
To the Editor: Dr. Friedman recommends that dehy-
drated children requiring intravenous therapy should re-
ceive hypotonic fluids with a sodium concentration of
3 mEq per 100 ml, after initially receiving bolus ther-
apy with isotonic fluid [1]. A recent report revealed that
many children treated in this fashion developed acute hy-
ponatremia [2]. Dr. Friedman is also incorrect when stat-
ing that most cases of hospital-acquired hyponatremia
resulted when “maintenance therapy was applied erro-
neously.” By Dr. Friedman’s own calculations, 0.45%
sodium chloride would be used for the treatment of
dehydration according to the deficit therapy approach.
Dr. Friedman offers no data to support the safety of us-
ing hypotonic fluid in volume-depleted children. It makes
no physiologic sense to administer hypotonic fluids to
patients with a hemodynamic stimulus for vasopressin
production.
The recommendations of using 3 mEq of sodium chlo-
ride per 100 mL of parenteral fluids are based on the
sodium content of human and cow milk [3]. This is far
less than the sodium content in the standard American
diet and has no applicability to the hospitalized child who
may have impaired free water excretion. The safety of
this approach has never been demonstrated in the hos-
pitalized children. What we do know is that there have
been numerous deaths resulting from hypotonic fluid ad-
ministration, prompting us to recommend the use of 0.9%
sodium chloride in parenteral fluid as prophylaxis against
hospital-acquired hyponatremia [4]. Dr. Friedman is crit-
ical of our recommendations, stating that “high volumes”
of fluid could result in fluid overload. We have never
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recommended high volumes of fluid administration, and
have recommended fluid restriction for diseases where
fluid overload could develop.
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Active vitamin D agents
and refractory
hyperparathyroidism in
dialysis patients
To the Editor: In the March 2005 issue of Kidney Inter-
national, Nakanishi et al [1] presented a very interesting
study showing that only serum levels of fibroblast growth
factor-23 (FGF-23) were significantly related to the prog-
nosis of parathyroid function in dialysis patients. The fac-
tors they included in their stepwise regression analysis
were serum FGF-23, calcium, phosphate, intact PTH, in-
tact osteocalcin, bone-specific alkaline phosphatase lev-
els, age, and dialysis vintage [1]. They did not include
treatment with active vitamin D agents, even though
the pretreatment serum FGF-23 levels were significantly
higher in those patients (47 out of 103) who were receiv-
ing vitamin D. A very recent paper by Foley et al [2]
showed that parathyroidectomy was associated, among
other factors, also with the previous use of IV vitamin D
(hazards ratio 2.44, P < 0.0001). Furthermore, we showed
that nodular hyperplasia of parathyroid glands was signif-
icantly associated with IV calcitriol pulse therapy (CPT)
in hemodialysis patients [3]. The simplest explanation for
the paradoxic association between this histologic pattern
and IV CPT could be that CPT is often attempted as
a “final” nonsurgical strategy when parathyroidectomy
is being considered [2]. On the contrary, we hypothe-
sized that, paradoxically, long-term IV CPT might be
among the factors determining nodular hyperplasia: in
fact, a disturbed and/or decreased action of long-term
IV CPT at the level of the parathyroid cell might cause
progression into the cell cycle and a disinhibition of c-
myc expression, leading to a more aggressive nodular
type proliferation of parathyroid glands [4]. Therefore,
we kindly ask Nakanishi et al to reanalyze their data, in-
cluding vitamin D treatment in their stepwise regression
analysis.
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Reply from the Authors
Thank you for your interest in our recent paper [1].
We agree with you that the cumulative dosage of active
vitamin D therapy may correlate with the severity of sec-
ondary hyperparathyroidism. However, we believe that
the more intensive vitamin D therapy should be the con-
sequence, but not the cause, of the nodular transforma-
tion of parathyroid cells, since such cells displayed less
sensitivity to vitamin D [2].
We have reported that the use of active vitamin D
agents may be related to the increased serum FGF-23 lev-
els in dialysis patients [1, 3, 4]. Therefore, we needed to
avoid applying FGF-23 and active vitamin D therapy to-
gether as independent variables when performing a step-
wise regression analysis. Although it may be possible to
perform a stepwise analysis applying active vitamin D
therapy instead of FGF-23, it must be “active vitamin D
therapy throughout the observation period,” but not “ac-
tive vitamin D therapy at the beginning of the observation
period.”
Furthermore, the physicians in charge changed treat-
ment strategy depending upon the plasma intact PTH
levels in our study. Accordingly, “active vitamin D ther-
apy throughout the observation period” was obviously a
